|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02348 DAWNRAYS PHARMA
Nominal 
1.210 -0.010 (-0.820%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 577,447 | -11.151% | 1,151,145 | 1,277,682 | 1,165,155 | 1,024,270 |
| Cost of Sales | (239,535) | -16.849% | (509,626) | (504,131) | (483,893) | (473,625) |
| Gross Profit | 337,912 | -6.615% | 641,519 | 773,551 | 681,262 | 550,645 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (3,696) | -81.791% | (40,933) | (61,905) | (46,418) | (18,771) | |
| Profit / (Loss) before Taxation | 556,752 | 70.151% | 414,057 | 438,408 | 439,323 | 331,298 | |
| Taxation | (65,169) | -10.778% | (91,390) | (82,557) | (85,160) | (66,505) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 1,463 | -17.391% | 3,333 | 2,206 | 4,012 | 3,337 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 493,046 | 92.640% | 326,000 | 358,057 | 358,175 | 268,130 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (12,838) | 26.946% | (24,938) | (19,004) | (19,171) | (12,250) |
| Depreciation & Amortisation | 41,868 | 13.187% | 83,893 | 66,410 | 57,545 | 56,008 |
| Directors' Emoluments | -- | -- | 2,973 | 3,089 | 9,667 | 10,861 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 32.860 | 92.501% | 21.740 | 23.890 | 23.920 | 17.360 |
| DPS (cts) | 1.369 | -- | 7.262 | 7.666 | 6.513 | 9.702 |
| Dividend Payout Ratio (%) | 4.166% | -- | 33.405% | 32.087% | 27.226% | 55.888% |
| Cash flow per share ($) | -- | -- | 0.226 | 0.290 | 0.263 | 0.196 |
| NBV per share ($) | 2.178 | -- | 1.903 | 1.763 | 1.589 | 1.433 |
| Remarks: | Real time quote last updated: 28/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 493,046,000 |
| %Change | 92.640% |
| EPS / (LPS) | RMB 0.329 |
| NBV Per Share (¥) | RMB 2.178 |